Research Article

The Role of the Basal Core Promoter (BCP) and Precore Codon 28 Mutations in the Treatment Response to the Pegylated Interferon
  • Şükran KÖSE
  • Süheyla Serin SENGER
  • Gülsün ÇAVDAR
  • Pelin ADAR
Viral Hepat J 2014; 20: 19-22 DOI: 10.4274/Vhd.74946
Relationship between HBV-DNA Level and Treatment Success in HBeAg Negative Patients Treated with Pegylated Interferone
  • Ertuğrul GÜÇLÜ
  • Nazan TUNA
  • Mehmet YAHYAOĞLU
  • Oğuz KARABAY
Viral Hepat J 2012; 18: 60-63 DOI: 10.4274/Vhd.22932
The Effectivity of Combination of Standard Interferon-a + Ribavirin and Pegylated Interferon-a + Ribavirin Therapy in Patients with Chronic Hepatitis C
  • Nail ÖZGÜNES
  • Fatma SARGIN
  • Saadet YAZICI
  • Nüket CEYLAN
  • Ayse Canan ÜÇISIK
  • Pinar ERGEN
  • Arzu DOGRU
  • Özlem AYDIN
Viral Hepat J 2006; 11: 61-64
The Evaluation of Pegylated Interferon Therapy in Patients with Chronic Hepatitis Delta
  • Ayşe ALBAYRAK
  • Muharrem COŞKUN
  • Ahmet UYANIKOĞLU
  • Yasin BAYIR
  • Havva YILMAZ
  • Yunus İlyas KİBAR
  • Ahmet TAY
  • Fatih ALBAYRAK
Viral Hepat J 2012; 18: 68-70 DOI: 10.4274/Vhd.32032
Evaluation of 219 Patients with Chronic Hepatitis C Receiving Pegylated Interferon + Ribavirin Treatment
  • Nevil AYKIN
  • Figen ÇAĞLAN ÇEVİK
  • Hasan NAZ
  • Pınar KORKMAZ
  • Tercan US
Viral Hepat J 2013; 19: 71-75 DOI: 10.4274/Vhd.77486
Hepatitis C Prevalence and Responses to Pegylated Interferon + Ribavirin Treatment Among Prisoners
  • Hasan Selçuk ÖZGER
  • Ömer KARAŞAHİN
  • Mehmet Armağan TOY
  • Sibel İBA YILMAZ
  • Kenan HIZEL
Viral Hepat J 2017; 23: 71-75 DOI: 10.4274/vhd.0007

Research Article

The Long-term (10.6 years) Outcome of Hepatitis C patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin
  • Osman Özdoğan
  • Serkan Yaraş
Viral Hepat J 2020; 26: 22-27 DOI: 10.4274/vhd.galenos.2019.2019.0042
Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
  • Handan ALAY
  • Kemalettin ÖZDEN
  • Serpil EROL
  • Neslihan ÇELİK
  • Emine PARLAK
  • Mehmet PARLAK
Viral Hepat J 2018; 24: 25-42 DOI: 10.4274/vhd.2017.0016
Examination of Mutations in the HBsAg and Polymerase Genes Induced by Pegylated Interferon Alpha and Oral Antivirals Used in the Treatment of Chronic Hepatitis B
  • Elif Sargın Altunok
  • Sila Akhan
  • Murat Sayan
Viral Hepat J 2020; 26: 141-150 DOI: 10.4274/vhd.galenos.2020.2020.0017

Case Report

Development of Acute Pancreatitis Due to Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis B: A Case Report
  • Şükran KÖSE
  • Melda TÜRKEN
  • Mehmet TANRISEV
  • Gülgün AKKOÇLU
Viral Hepat J 2015; 21: 35-37 DOI: 10.4274/vhd.69875
Chronic Hepatitis C Treatment-Related Skin Rash: A Report of Two Cases
  • Tuğba ARSLAN GÜLEN
  • Ayfer İMRE
Viral Hepat J 2015; 21: 59-61 DOI: 10.4274/vhd.96268
Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report
  • Tugba SARI
  • Suda Tekin KORUK
  • Fatih TEMOÇIN
Viral Hepat J 2014; 20: 81-84 DOI: 10.4274/vhd.38358
Pegylated Interferon Alpha 2a Associated Dermatitis: A Case Report
  • Saygın NAYMAN ALPAT
  • Salih Atakan NEMLİ
  • Nurettin ERBEN
  • Elif DOYUK KARTAL
  • İlhan ÖZGÜNEŞ
  • Gaye USLUER
Viral Hepat J 2009; 14: 116-118
Sensorineural Hearing Loss Due to Pegylated Interferon Alfa/Ribavirin Therapy: A Case Report
  • Tuğba SARI
  • Süda TEKİN KORUK
  • Alaaddin ZİREK
Viral Hepat J 2012; 18: 123-125 DOI: 10.4274/Vhd.66376